Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress
- Q1 2023 revenue was
$7.4 million , which represents a 30% increase over Q1 2022 - Installed base of 259 Saphyr® systems totaled as of Q1 2023, which represents a 47% increase over Q1 2022
- Sold 5,226 nanochannel array flowcells in Q1 2023, which represents a 62% increase over the number of flowcells sold in Q1 2022
- Conference call today,
May 9, 2023 at4:30 PM ET
Q1 2023 Highlights
- Installed base of Saphyr® systems totaled 259 at the end of the first quarter 2023, which was an increase of 19 systems over the fourth quarter of 2022 and represents a 47% increase over the 176 installed systems reported at the end of the first quarter of 2022.
- 5,226 nanochannel array flowcells sold during the first quarter, which represents a 9% increase over the 4,781 flowcells sold during the fourth quarter of 2022 and represents an increase of 62% over the 3,225 flowcells sold during the first quarter of 2022.
- Announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano’s optical genome mapping (OGM) workflow; collaboration is expected to significantly improve data processing speed while reducing time and cost associated with secondary analysis of OGM data.
- Announced that an original equipment manufacturing (OEM) partner in
China , Beijing Genome Precision Technology (BGPT), a comprehensive molecular diagnostics company, obtained reagent class I registrations fromChina's National Medical Products Administration (NMPA) for Bionano's DNA extraction kit and labeling products for use in in vitro diagnostics (IVD); which allows BGPT to market these products to independent clinical labs inChina . - Significantly expanded 4-day 2023 Symposium year-over-year: 31 oral presentations on OGM; 114 countries represented; 69 scientific posters; and an average of 750 daily attendees, a 32% increase over 2022 daily attendance.
- Held first-ever Strategy Day at Nasdaq MarketSite in
New York , where Bionano’s management team delivered an in-depth review of the Company’s strategy and growth initiatives and outlined our three-year financial targets, including 30-50% compound annual growth in revenues. Key opinion leaders fromMD Anderson Cancer Center ,Augusta University , Boston Children’s Hospital, Children’s Hospital Los Angeles,University of Toronto andSanford Burnham Prebys Institute , spoke about their experience using OGM in translational and clinical research areas including cancer, genetic disease and cell bioprocessing and how it’s different from other technologies, such as next-generation sequencing (NGS) and long read sequencing (LRS). All presentations from the event were recorded and are available to view in the Investors section of the Bionano website. - Key publications support OGM’s utility for research applications including cancer and genetic disease:
- Three publications from European institutions collectively illustrated the continued development of data supporting OGM as an alternative to traditional cytogenetic methods for the analysis of hematological malignancies. The studies confirmed OGM’s high level of concordance and ability to identify relevant variants that are not detected by traditional methods but that could have an impact on clinical research, potentially leading to improved patient management, including therapy selection and overall risk assessment.
- Researchers from
Augusta University published the first study to evaluate OGM as a method to identify rare structural variants (SVs) that might contribute to the development of Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome. OGM detected rare SVs with potential disease relevance in 19.5% of samples and identified mosaicism in 21.4% of confirmed variants. Study authors also used OGM to identify the first described female with MRKH to possess mosaicism for trisomy 12, which potentially confirms a genetic driver that researchers have thought to be linked to MRKH. - A pre-print publication described the multi-site evaluation of OGM for postnatal genetic disorders in 560 unique samples, with a study total of 749 unique samples to-date from 1,037 datapoints and showed 99.6% concordance with standard of care (SOC) methods and showed 42% more reportable findings in samples suspected of a genetic disorder and 32% more reportable findings in samples suspected of autism spectrum disorders (ASD), when compared with traditional cytogenetic methods.
- A published interim report described the multi-site evaluation of OGM for prenatal genetic disorders in 200 samples across 9 sites, assessing performance and reproducibility of OGM versus SOC methods. The report showed OGM was comparable, in a single assay, to the results of two separate SOC tests in 56% of cases and to three separate SOC tests in 19% of cases, with 100% concordance for all calls and variant calls, and 100% reproducibility of analytical quality control and variant calls from site-to-site.
- A study from Institut Curie analyzed OGM as a method to identify homologous recombination deficiency (HRD) in breast cancer samples. The study reported that OGM successfully assessed levels of HRD in all samples, potentially improving genomic profiling of solid tumor samples and offering an efficient, lower-cost method of detecting HRD with greater sensitivity than whole genome sequencing (WGS).
“We are pleased with our Q1 2023 results, which include record revenues for any Bionano Q1 and mark the tenth consecutive quarter of year-over-year revenue growth, dating back to the fourth quarter of 2020. This quarter’s expansion in the Saphyr system installed base, combined with the increasing number of publications on OGM that reported consistently high concordance with traditional cytogenetic methods across key applications within cytogenomics and genomics research, provide additional indications of the potential for further OGM adoption,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano. “We believe our achieved and planned product introductions, together with the growing evidence of OGM utility shown in recent publications, lay the foundation for potential further penetration of our target markets and revenue growth.”
Q1 2023 Financial Highlights
- Total revenue for the first quarter of 2023 was
$7.4 million , an increase of 30% compared to the first quarter of 2022. - GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022. The increase was primarily due to year-over-year improvements in our flowcell chip production yield. First quarter 2023 non-GAAP¹ gross margin was 30%, compared to 15% from the first quarter of 2022. First quarter 2023 non-GAAP gross margin excludes
$146,000 in stock-based compensation. - First quarter 2023 GAAP operating expense was
$39.9 million , compared to$30.8 million in the first quarter of 2022. First quarter 2023 non-GAAP operating expense was$33.6 million , compared to$24.2 million in the first quarter of 2022. First quarter 2023 non-GAAP operating expense excludes$3.7 million in stock-based compensation,$1.8 million in amortization of intangibles, and a$0.8 million increase in the estimated fair value of the contingent consideration liabilities primarily related to the acquisition of Purigen. - Cash, cash equivalents, and available-for-sale securities were
$95.8 million as ofMarch 31, 2023 compared to cash, cash equivalents and available-for-sale securities of$113.2 million as ofDecember 31, 2022 .
Plan to Reduce Future Cash Expenditures
Bionano recently undertook a strategic review of our operations, and today we announce our initiative to reduce cash expenditures by approximately
Webcast Details
| Webcast Details | |
| Date: | |
| Time: | |
| Live Call: | Toll-Free: (800) 715-9871, Conference ID: 4068548 |
| Webcast: | https://edge.media-server.com/mmc/p/tw7qar43 |
Participants should register at the link above in advance of the call, and then click the webcast link before the call begins. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
About
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research and for other applications including bioprocessing. Through its Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Through its Purigen Biosystems business, the Company offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com or www.biodiscovery.com.
Non-GAAP Financial Measures
To supplement Bionano’s financial results reported in accordance with
Bionano believes that non-GAAP gross margin and non-GAAP operating expense are useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing operating performance and identifying operating trends in its business. Bionano uses non-GAAP gross margin and non-GAAP operating expense internally to facilitate period-to-period comparisons and analysis of its operating performance in order to understand, manage and evaluate its business and to make operating decisions. Accordingly, Bionano believes these measures allow for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Bionano in this press release and the accompanying reconciliation table have limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
For a reconciliation of non-GAAP gross margin and non-GAAP operating expense to gross margin and operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this release.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “estimate,” “expect,” “may,” “plan,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding product uptake, revenue growth, market development and increased OGM adoption, including through publications highlighting the utility and applications of OGM; our growth prospects and future financial and operating results, including our compound annual growth in revenues; the growth of our installed Saphyr system base; the sales of our flowcell consumables and the other expectations related thereto; our ability to meet our stated goals, including to drive value and penetrate into our target markets; our commercial expectations, including the potential market opportunity for structural variation analysis and OGM; the anticipated benefits and success of our collaboration efforts, including the opportunities offered by our anticipated collaborations with NVIDIA; the expected benefits of our partner’s IVD registrations in
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
+1 (858) 888-7625
IR@bionano.com
1 Non-GAAP gross margin and non-GAAP operating expense are non-GAAP financial measures. For a description of these non-GAAP financial measures, please refer to “Non-GAAP Financial Measures”.
| Condensed Consolidated Balance Sheet (Unaudited) |
||||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,104,000 | $ | 5,091,000 | ||||
| Investments | 91,704,000 | 108,095,000 | ||||||
| Accounts receivable, net | 6,780,000 | 7,022,000 | ||||||
| Inventory | 33,113,000 | 29,761,000 | ||||||
| Prepaid expenses and other current assets | 6,856,000 | 7,329,000 | ||||||
| Total current assets | 142,557,000 | 157,298,000 | ||||||
| Restricted cash | 400,000 | 400,000 | ||||||
| Property and equipment, net | 19,050,000 | 18,029,000 | ||||||
| Operating lease right-of-use asset | 7,062,000 | 7,222,000 | ||||||
| Financing lease right-of-use asset | 3,657,000 | 3,707,000 | ||||||
| Intangible assets, net | 39,351,000 | 41,143,000 | ||||||
| 77,289,000 | 77,289,000 | |||||||
| Other long-term assets | 2,785,000 | 2,414,000 | ||||||
| Total assets | $ | 292,151,000 | $ | 307,502,000 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 15,780,000 | $ | 12,534,000 | ||||
| Accrued expenses | 9,250,000 | 10,552,000 | ||||||
| Contract liabilities | 1,127,000 | 871,000 | ||||||
| Operating lease liability | 2,235,000 | 2,260,000 | ||||||
| Finance lease liability | 282,000 | 285,000 | ||||||
| Contingent consideration | 9,461,000 | 9,382,000 | ||||||
| Total current liabilities | 38,135,000 | 35,884,000 | ||||||
| Operating lease liability, net of current portion | 5,043,000 | 5,504,000 | ||||||
| Finance lease liability, net of current portion | 3,612,000 | 3,619,000 | ||||||
| Contingent consideration | 13,680,000 | 12,970,000 | ||||||
| Long-term contract liabilities | 194,000 | 127,000 | ||||||
| Total liabilities | 60,664,000 | 58,104,000 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 31,000 | 30,000 | ||||||
| Additional paid-in capital | 617,960,000 | 599,207,000 | ||||||
| Accumulated deficit | (385,839,000 | ) | (348,715,000 | ) | ||||
| Accumulated other comprehensive loss | (665,000 | ) | (1,124,000 | ) | ||||
| Total stockholders’ equity | 231,487,000 | 249,398,000 | ||||||
| Total liabilities and stockholders’ equity | $ | 292,151,000 | $ | 307,502,000 | ||||
| Condensed Consolidated Statement of Operations (Unaudited) | ||||||||
| Three Months Ended |
||||||||
| 2023 | 2022 | |||||||
| Revenue: | ||||||||
| Product revenue | $ | 5,447,000 | $ | 4,206,000 | ||||
| Service and other revenue | 1,968,000 | 1,490,000 | ||||||
| Total revenue | 7,415,000 | 5,696,000 | ||||||
| Cost of revenue: | ||||||||
| Cost of product revenue | 3,858,000 | 3,576,000 | ||||||
| Cost of service and other revenue | 1,487,000 | 1,259,000 | ||||||
| Total cost of revenue | 5,345,000 | 4,835,000 | ||||||
| Operating expenses: | ||||||||
| Research and development | 13,937,000 | 10,527,000 | ||||||
| Selling, general and administrative | 25,976,000 | 20,277,000 | ||||||
| Total operating expenses | 39,913,000 | 30,804,000 | ||||||
| Loss from operations | (37,843,000 | ) | (29,943,000 | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | 704,000 | 110,000 | ||||||
| Interest expense | (76,000 | ) | (77,000 | ) | ||||
| Other income (expense) | 117,000 | (33,000 | ) | |||||
| Total other income (expense) | 745,000 | — | ||||||
| Loss before income taxes | (37,098,000 | ) | (29,943,000 | ) | ||||
| Provision for income taxes | (26,000 | ) | (9,000 | ) | ||||
| Net loss | $ | (37,124,000 | ) | $ | (29,952,000 | ) | ||
| Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense (Unaudited) | ||||||||
| Three Months Ended |
||||||||
| 2023 | 2022 | |||||||
| GAAP gross margin: | ||||||||
| GAAP revenue | $ | 7,415,000 | $ | 5,696,000 | ||||
| GAAP cost of revenue | 5,345,000 | 4,835,000 | ||||||
| GAAP gross profit | 2,070,000 | 861,000 | ||||||
| GAAP gross margin % | 28 | % | 15 | % | ||||
| Adjusted non-GAAP gross margin: | ||||||||
| GAAP revenue | 7,415,000 | 5,696,000 | ||||||
| GAAP cost of revenue | 5,345,000 | 4,835,000 | ||||||
| Stock-based compensation expense | (146,000 | ) | — | |||||
| Adjusted non-GAAP cost of revenue | 5,199,000 | 4,835,000 | ||||||
| Adjusted non-GAAP gross profit | 2,216,000 | 861,000 | ||||||
| Adjusted non-GAAP gross margin % | 30 | % | 15 | % | ||||
| GAAP operating expense | $ | 39,913,000 | $ | 30,804,000 | ||||
| GAAP selling, general and administrative expense | 25,976,000 | 20,277,000 | ||||||
| Stock-based compensation expense | (2,379,000 | ) | (1,774,000 | ) | ||||
| Intangible asset amortization | (1,792,000 | ) | (1,419,000 | ) | ||||
| Change in fair value of contingent consideration | (789,000 | ) | (79,000 | ) | ||||
| Adjusted non-GAAP selling, general and administrative expense | $ | 21,016,000 | $ | 17,005,000 | ||||
| GAAP research and development expense | $ | 13,937,000 | $ | 10,527,000 | ||||
| Stock-based compensation expense | (1,357,000 | ) | (3,328,000 | ) | ||||
| Adjusted non-GAAP research and development expense | 12,580,000 | 7,199,000 | ||||||
| Total adjusted non-GAAP operating expense | $ | 33,596,000 | $ | 24,204,000 | ||||
Source: Bionano Genomics